Check out your Company Bowl for anonymous work chats.
Verily’s Andrew Trister delivered the keynote address to a full house at the H7 JPM Investment Forum & Demo Day. He explored the evolution of AI tools in medicine, their historical applications, and the transformative potential they hold for the healthcare landscape in 2025 and beyond.
“By incorporating the existing data available within the health system with data that is person-generated (through wearables, or other types of data) we will have an unprecedented approach to building proactive [AI] agents that can help a person better understand their own health and disease,” said Andrew Trister, Verily Chief Medical and Scientific Officer. Read more of his 2025 predictions for advancements in AI, which emphasize potential benefits in oncology and chronic disease management.
With data from wastewater surveillance, public health officials can understand what pathogens are present and make informed decisions about how to support communities. Watch how Verily works with wastewater epidemiologists and treatment facilities to turn water into wisdom in the Las Vegas Valley.
What will 2025 bring for employers? Verily’s Chief Clinical Officer and Head of Health Equity Vindell Washington sat down with FierceHealthcare to discuss challenges and opportunities for employers in the year ahead, including the need for more comprehensive chronic condition management programs.
We’re thrilled to see Verily CEO Stephen Gillett be named to D CEO's Dallas 500, a list of the 500 most significant and influential leaders in North Texas. Verily is proud to be part of the growing DFW healthcare and tech ecosystem and we look forward to our continued contributions in the years ahead. Congratulations to Stephen and all the other honorees!
Our Chairman and CEO Stephen Gillett will be at the J.P. Morgan Healthcare Conference discussing Verily's precision health strategy on Tuesday, January 14th at 11am PDT.
🎥 Presenting Verily N of 1: Eye on the Future Watch how Verily is transforming diabetes care.
New sleep research from Verily published in Frontiers in Sleep 😴 Changes in sleep are clinically meaningful components for tracking mental and cardiovascular health. Polysomnography (PSG) is the standard tool to assess sleep but it is resource-intensive and challenging to administer. Verily evaluated the performance of a wrist-worn wearable, Verily Study Watch (VSW), in comparison to PSG for measuring sleep, showing the potential of VSW.
The use of digital health technologies (DHTs) in registries has the potential to improve evidence generation by reflecting real-world patient-centered outcomes. However, there are challenges to implementing DHTs, which has prevented broad adoption. Learn what some of them are, along with proposed solutions. The details, outlined in a paper published in The Lancet Digital Health, are based on the collective experiences of co-authors representing the Health Data Research UK (HDR UK), Verily and the patient community.
At Verily, we are committed to generating patient-centered digital measures of health into meaningful, real-world evidence for accelerating research and development. Adopting a framework for validating novel clinical digital measures resources will not only enhance the quality and effectiveness of sensor-based digital health technologies evaluation but also lead to significant improvements in patient care and health outcomes.
